Molecular biology of melanoma

Journal of the American Academy of Dermatology

Volumn 67, Issue 5, 2012, Pages 1049-1054

  Swick, Julie M ^a   Maize, John C ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b DermPath Diagnostics of South Carolina   (United States)

Author keywords

BRAF; KIT; Melanoma; Melanoma mutations; Mitogen activated protein kinase; RAS

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STEM CELL FACTOR RECEPTOR;

GENETICS; HUMAN; MELANOMA; ONCOGENE RAS; RETINOBLASTOMA; REVIEW; SKIN TUMOR;

GENES, RAS; HUMANS; MELANOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RETINOBLASTOMA; SKIN NEOPLASMS;

EID: 84872681396     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.06.047     Document Type: Review

References (22)

1. National Cancer Institute. Melanoma home page. Available from URL: http://www.cancer.gov/cancertopics/types/melanoma. Accessed May 16, 2010
2. Shoo A, Sagebiel R, Kashani-Sabet M. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol 2010;62:751-6
3. Inamdar G, Madhunapantula S, Robertson G. Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochem Pharmacol 2010;80:624-37
4. van Dijk M, Bernsen M, Ruiter D. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and Spitzoid melanoma. Am J Surg Pathol 2005; 29:1145-51
5. Garrido M, Bastian B. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010;130:20-7
6. Jovanovic B, Egyhazi S, Eskandarpour M, Ghiorzo P, Palmer JM, Bianchi Scarra G, et al. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. J Invest Dermatol 2010;130: 618-20
7. Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD, et al. Dissection of RAS downstream pathways in melanomagenesis: A role for Ral in transformation. Oncogene 2010;29:2449-56
8. Takata M, Saida T. Genetic alterations in melanocytic tumors. J Dermatol Sci 2006;43:1-10
9. Dong J, Phelps R, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63: 3883-5
10. Zhong Z, Yeow WS, Zou C, Wassell R, Wang C, Pestell RG, et al. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res 2010;70:2105-14
11. Milagre C, Dhomen N, Geyer F, Hayward R, Lambros M, Reis-Filho JS, et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res 2010;70:5549-57
12. Heidorn S, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas L, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21
13. Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescencelike cell cycle arrest of human nevi. Nature 2005;436: 720-4
14. Wajapeyee N, Serra R, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132:363-74
15. Haferkamp S, Tran S, Becker T, Scurr L, Kefford RF, Rizos H. The relative contributions of the p53 and pRb pathways in oncogene induced melanocyte senescence. Aging (Albany NY) 2009;1:542-56
16. Hacker E, Hayward N, Dumenil T, James M. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: Findings from an Australian population. J Invest Dermatol 2010;130:241-8
17. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008;6: E120
18. McKenzie H, Fung C, Becker T, Irvine M, Mann G, Kefford R, et al. Predicting functional significance of cancer-associated p16INK4a mutations in CDKN2A. Hum Mutat 2010;31:692-701
19. Box N, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 2008;21:525-33
20. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer 2011;104:392-8
21. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK of N-RAS up-regulation. Nature 2010; 468:973-7
22. Woodman S, Davies M. Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 2010;80:568-74.